K J Shaw
- The oxazolidinones: past, present, and futureKaren Joy Shaw
Trius Therapeutics, Inc, Department of Biology, San Diego, California 92121, USA
Ann N Y Acad Sci 1241:48-70. 2011..However, maintaining potency against strains carrying the mobile cfr gene poses a challenge for the oxazolidinone class, as well as other 50S ribosome inhibitors that target the peptidyl transferase center...
- In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strainsK J Shaw
Trius Therapeutics, Inc, 6310 Nancy Ridge Drive, Suite 105, San Diego, CA 92121, USA
Antimicrob Agents Chemother 52:4442-7. 2008..A model of TR-700 binding to 23S rRNA suggests that the increased potency of TR-700 is due to additional target site interactions and that TR-700 binding is less reliant on target residues associated with resistance to LZD...
- Genetic environment and stability of cfr in methicillin-resistant Staphylococcus aureus CM05Jeffrey B Locke
Trius Therapeutics, Inc, San Diego, California, USA
Antimicrob Agents Chemother 56:332-40. 2012..Minicircles resulting from the ermB recombination event and the novel association of cfr with the pSM19035 plasmid system support the potential for the continued dissemination of cfr...